Drugs

, Volume 5, Issue 4, pp 261–291 | Cite as

Antiarrhythmic Agents I: Mechanisms of Action and Clinical Pharmacology

  • Dean T. Mason
  • A. N. DeMaria
  • E. A. Amsterdam
  • R. Zelis
  • R. A. Massumi
Review Article

Summary

In the application of antiarrhythmic drugs in patients, a thorough knowledge of their pharmacological effects greatly aids the clinician in the more rational selection of the drug or combination of drugs in terms of expected benefits, favourable additive actions, and contra-indications. Each of the agents depresses disorders of rapid impulse formation (repetitive ectopic pacemaker activity) by reducing diastolic depolarisation and thereby diminishing automaticity, and inhibits disorders of impulse conduction (re-entry tachyarrhythmias) by altering conduction velocity and refractory period and thereby interrupting reciprocal excitation pathways.

Concerning unidirectional block perpetuating re-entry mechanisms, group I drugs (quinidine, procainamide, propranolol, bretylium and potassium) produce bidirectional block by slowing conduction velocity, while group II drugs (lignocaine and phenytoin or diphenylhydantoin) abolish localised block by enhancing conduction velocity. In addition to depression of automaticity, agents in both groups increase functional refractoriness relative to action potential duration due to alterations in membrane responsiveness. Quinidine, procainamide and bretylium directly prolong refractory period; in contrast, lignocaine, phenytoin, and propranolol directly reduce this period. Both propranolol and bretylium possess powerful antiadrenergic actions, while quinidine and procainamide produce anticholinergic effects. Accompanying their antiarrhythmic actions, quinidine, procainamide, and propranolol worsen atrioventricular block, whereas this property in the atrioventricular node usually is not influenced by lignocaine and is accelerated by phenytoin.

Quinidine and procainamide are broad-spectrum antiarrhythmic drugs which are effective in both supraventricular and ventricular tachyarrhythmia while propranolol and phenytoin are useful in supraventricular and ventricular disorders. Propranolol is particularly efficacious against supraventricular arrhythmias and phenytoin more beneficial in disturbances of ventricular rhythm. Lignocaine has little action in atrial disorders but markedly suppresses ventricular irritability. Bretylium may successfully terminate refractory ventricular rhythm abnormalities. Phenytoin propranolol lignocaine and potassium possess the most favourable electrophysiological properties for correction of tachyarrhythmias due to digitalis toxicity.

Key Words

Antiarrhythmic drugs: clinical application Antiarrhythmic drugs: modes of action Antiarrhythmic drugs: pharmacokinetics Antiarrhythmic drugs: toxicity Cardiac arrhythmias: pathophysiology Cardiac electrophysiology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amsterdam, E.A.; Gorlin, R. and Wolfson, S.: Evaluation of long-term use of propranolol in angina pectoris. Journal of the American Medical Association 210: 103 (1969).PubMedCrossRefGoogle Scholar
  2. Amsterdam, E.A.; Hughes, J.L.; Mansour, E.; Salel, A.F.; Bonanno, J.A.; Zelis, R. and Mason, D.T.: Circulatory effects of practolol: Selective cardiac beta adrenergic blockade in arrhythmias and angina pectoris. Clinical Research 19: 109 (1971).Google Scholar
  3. Amsterdam, E.; Mansour, E.; Hughes, J.; Bonanno, J.; Zelis, R.; Massumi, R.A. and Mason, D.T.: Present status of glucagon and bretylium tosylate; in Russek and Zohman Changing Concepts in Cardiovascular Diseases, p.215 (Williams and Wilkins, Baltimore 1972a).Google Scholar
  4. Amsterdam, E.A.; Massumi, R.A.; Zelis, R. and Mason, D.T.: Use of bretylium tosylate in the management of cardiac arrhythmias. Heart and Lung 1: 269 (1972b).Google Scholar
  5. Atkinson, J.A.: Clinical use of blood levels of cardiac drugs. Modern Concepts of Cardiovascular Disease 42: 1–4 (1973).PubMedGoogle Scholar
  6. Ayres, S.M. and Grace, W.J.: Inappropriate ventilation and hypoxemia as causes of cardiac arrhythmias. American Journal of Medicine 46: 495–505 (1969).PubMedCrossRefGoogle Scholar
  7. Bacaner, M.: Bretylium tosylate for suppression of induced ventricular fibrillation. American Journal of Cardiology 17: 528 (1966).PubMedCrossRefGoogle Scholar
  8. Bacaner, M.R.: Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. American Journal of Cardiology 21: 530 (1968).PubMedCrossRefGoogle Scholar
  9. Bigger, T.; Bassett, A.L. and Hoffman, B.: Electrophysiological effects of diphenylhydantoin on canine Purkinje fibres. Circulation Research 22: 221 (1968).PubMedCrossRefGoogle Scholar
  10. Bigger, J.T.Jr. and Heissenbuttel, R.H.: The use of procainamide and lidocaine in the treatment of cardiac arrhythmias. Progress in Cardiovascular Disease 11: 515 (1969).CrossRefGoogle Scholar
  11. Bigger, J.T.Jr. and Heissenbuttel, R.H.: Clinical use of antiarrhythmic drugs. Postgraduate Medicine 47: 119 (1970a).PubMedGoogle Scholar
  12. Bigger, J.T.Jr. and Mandel, W.J.: Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibres. Journal of Clinical Investigation 49: 63 (1970b).PubMedCrossRefGoogle Scholar
  13. Bigger, J.T.Jr. and Jaffe, C.C.: The effect of bretylium tosylate on the electrophysiologic properties of ventricular muscle and Purkinje fibres. American Journal of Cardiology 27: 82 (1971).PubMedCrossRefGoogle Scholar
  14. Choquet, Y.; Capone, R.; Mason, D.T.; Amsterdam, E.A. and Zelis, R.: Comparison of the beta adrenergic blocking properties and negative inotropic effects of oxyprenolol and propranolol in patients. American Journal of Cardiology 29: 257 (1972).CrossRefGoogle Scholar
  15. Cohen, L.S.; Rosenthal, J.; Homer, D.; Atkins, J.; Matthews, O. and Sarnoff, S.: Plasma levels of lidocaine after intramuscular administration. American Journal of Cardiology 29: 520–523 (1972).PubMedCrossRefGoogle Scholar
  16. Conn, H.L.Jr. and Luchi, R.J: Some cellular and metabolic considerations relating to the action of quinidine as a prototype antiarrhythmic agent. American Journal of Medicine 37: 685 (1964).PubMedCrossRefGoogle Scholar
  17. Conn, R.D.: Diphenylhydantoin sodium in cardiac arrhythmias. New England Journal of Medicine 272: 277 (1965).PubMedCrossRefGoogle Scholar
  18. Cooper, J.R.; Berlin, I.; Rovenstine, E.A. and Brodie, B.: The physiological disposition and cardiac effects of procainamide. Journal of Pharmacology and Experimental Therapeutics 102: 5 (1951).PubMedGoogle Scholar
  19. Damato, A.N.: Diphenylhydantoin: Pharmacological and clinical use. Progress in Cardiovascular Disease 12: 1 (1969).CrossRefGoogle Scholar
  20. Davis, L.D. and Temte, J.F.: Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibres of the dog. Circulation Research 2: 661(1968).CrossRefGoogle Scholar
  21. Day, H.W. and Bacaner, M.R.: Use of bretylium tosylate in the management of acute myocardial infarction. American Journal of Cardiology 27: 177 (1971).PubMedCrossRefGoogle Scholar
  22. DeMaria, A.N.; Fabregas, R.A.; Gray, D.; Jewett, M.; Tabaie, H.; Zelis, R.; Mason, D.T. and Massumi, R.A.: Ventriculo-atrial conduction in pacing and digitalis-induced ventricular tachycardia: Effects of vagal stimulation and vagotonic drugs. Clinical Research 21: 235 (1973).Google Scholar
  23. Dill, W.; Kazenko, L.; Wolf, L. and Glazko, A.: Studies on 5-5′ diphenylhydantoin in animals and man. Journals of Pharmacology and Experimental Therapeutics 118: 270 (1956).Google Scholar
  24. Dreifus, L.S.; Lim, H.F.; Watanabe, Y.; McKnight, E. and Frank, M.N.: Propranolol and quinidine in the management of ventricular tachycardia. Journal of the American Medical Association 204: 190 (1968).CrossRefGoogle Scholar
  25. Dunlop, D. and Shanks, R.G.: Selective blockage of adrenoceptive beta-receptors in the heart. British Journal of Pharmacology 32: 101 (1968).Google Scholar
  26. Fisch, C.; Knoebel, S.B.; Feigenbaum, H. and Greenspan, K.: Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Progress in Cardiovascular Disease 8: 387 (1966).CrossRefGoogle Scholar
  27. Fitzgerald, J.D.: Perspectives in adrenergic beta-receptor blockage. Clinical Pharmacology and Therapeutics 10: 292 (1969).PubMedGoogle Scholar
  28. Frankl, W.S. and Soloff, L.A.: Sotalol: A new, safe, beta-adrenergic receptor blocking agent. American Journal of Cardiology 22: 266 (1968).PubMedCrossRefGoogle Scholar
  29. Gibson, D. and Sowton, E.: The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Progress in Cardiovascular Disease 12: 16 (1969).CrossRefGoogle Scholar
  30. Harrison, D.C.; Braunwald, E.; Glick, G.; Mason, D.T.; Chidsey, C.A. and Ross, J.Jr.: Effects of beta adrenergic blockage on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29: 84 (1964).PubMedCrossRefGoogle Scholar
  31. Heifant, R.H.; Lau, S.H.; Cohen, S.I. and Damato, A.N.: Effects of diphenylhydantoin on atrioventricular conduction in man. Circulation 36: 686 (1967a).CrossRefGoogle Scholar
  32. Heifant, R.H.; Scherlag, B.J. and Damato, A.N.: Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium. Circulation 36: 119 (1967).CrossRefGoogle Scholar
  33. Heifant, R.H.; Scherlag, B.J. and Damato, A.N.: Diphenylhydantoin prevention of arrhythmias in the digitalis-sensitised dog after direct-current cardioversion. Circulation 37: 424 (1968).CrossRefGoogle Scholar
  34. Helfant, R.H.; Seuffert, G.W.; Patton, R.D.; Stein, E. and Damato, A.N.: The clinical use of diphenylhydantoin (Dilantin) in the treatment and prevention of cardiac arrhythmias. American Heart Journal 77: 315 (1969).PubMedCrossRefGoogle Scholar
  35. Hilmi, K.I. and Regan, T.J.: Relative effectiveness of anti-arrhythmic drugs in treatment of digitalis-induced ventricular tachycardia. American Heart Journal 76: 365 (1968).PubMedCrossRefGoogle Scholar
  36. Hoffman, B.F. and Cranefield, P.F.: Electrophysiology of the heart. (McGraw-Hill, New York 1960).Google Scholar
  37. Hoffman, B.F. and Bigger, J.T.Jr.: Antiarrhythmic drugs; in DiPalma Drill’s Pharmacology in Medicine, 4th ed (McGraw-Hill, New York 1971).Google Scholar
  38. Hollunger, G.: On the metabolism of lidocaine. II. Biotransformation of lidocaine. Acta Pharmacologica et toxicologica 17: 365 (1960).CrossRefGoogle Scholar
  39. Kleiger, R.E. and Lown, B.: Cardioversion and digitalis. II. Clinical studies. Circulation 33: 878 (1966).PubMedCrossRefGoogle Scholar
  40. Koppanyi, T.: The sedative, central analgesic and anti-convulsant action of local anesthetics. American Journal of the Medical Sciences 244: 646 (1962).PubMedGoogle Scholar
  41. Kutt, H. and Louis, S.: Anticonvulsant drugs II: Clinical pharmacological and therapeutic aspects. Drugs 4: 256 (1972).PubMedCrossRefGoogle Scholar
  42. Ladd, A.T.: Procainamide induced lupus erythematosus. New England Journal of Medicine 267: 1357 (1962).PubMedCrossRefGoogle Scholar
  43. Lazzara, R. and Abelleibra, J.L.: Intracellular recordings from infarcted canine endocardium. Federation Proceedings 31: 387 (1972).Google Scholar
  44. Levey, G.S. and Epstein, S.E.: Activation of adenyl cyclase by glucagon in cat and human heart. Circulation Research 24: 151 (1969).PubMedCrossRefGoogle Scholar
  45. Lown, B.: Electrical reversion of cardiac arrhythmias. British Heart Journal 29: 469–489 (1967).PubMedCrossRefGoogle Scholar
  46. Lucchesi, B.R.: The effects of pronethalol and its dextroisomer upon experimental cardiac arrhythmias. Journal of Pharmacology and Experimental Therapeutics 148: 94 (1965).PubMedGoogle Scholar
  47. Lucchesi, B.R.; Whitsit, L.S. and Stickney, J.L.: Anti-arrhythmic effects of beta adrenergic blocking agents. Annals of the New York Academy of Sciences 139: 940 (1969).CrossRefGoogle Scholar
  48. Mansour, E.; Mason, D.T.; Spann, J.F.Jr.; Zelis, R. and Amsterdam, E.A.: Clinical evaluation of anti-arrhythmic and hemodynamic properties of bretylium. Circulation 42: (Suppl. 3): 41 (1970).Google Scholar
  49. Mason, D.T. and Braunwald, E.: Mechanisms of action and therapeutic uses of cardiac drugs; in Fulton Modern Trends in Pharmacology and Therapeutics, p. 112 (Butterworths, London 1968).Google Scholar
  50. Mason, D.T.; Spann, J.F.Jr. and Zelis, R.: New developments in the understanding of the actions of the digitalis glycosides. Progress in Cardiovascular Disease 11: 443 (1969).CrossRefGoogle Scholar
  51. Mason, D.T.; Spann, J.F.Jr.; Zelis, R. and Amsterdam, E.A.: The clinical pharmacology and therapeutic applications of the antiarrhythmic drugs. Clinical Pharmacology and Therapeutics 11: 4: 460 (1970).PubMedGoogle Scholar
  52. Mason, D.T.; Spann, J.F.Jr.; Zelis, R. and Amsterdam, E.A.: Evolving concepts in the clinical pharmacology and therapeutic uses of the antiarrhythmic drugs; in Russek and Zohman Cardiovascular Therapy: The Art and Science, p. 112 (Williams and Wilkins, Baltimore 1971a).Google Scholar
  53. Mason, D.T.; Zelis, R.; Lee, G.; Hughes, J.L.; Span, J.F.Jr. and Amsterdam, E.A.: Current concepts and treatment of digitalis toxicity. American Journal of Cardiology 27: 546 (1971b).PubMedCrossRefGoogle Scholar
  54. Mason, D.T.; Amsterdam, E.A.; Massumi, R.A. and Zelis, R.: Recent advances in antiarrhythmic drugs: Clinical pharmacology and therapeutics; in Eliot The Acute Cardiac Emergency, p. 95 (Futura Publishing Co, Mount Kisco,New York 1972).Google Scholar
  55. Miller, R.; Amsterdam, E.; Massumi, R. et al.: Procainamide: Reappraisal of an old antiarrhythmic drug. Heart and Lung (in press, 1973).Google Scholar
  56. Moe, G. and Mendez, C.: Physiologic basis of premature beats and sustained tachycardias. New England Journal of Medicine 288: 250 (1973).PubMedCrossRefGoogle Scholar
  57. Myerberg, R.J.; Stewart, J.W. and Hoffman, B.F.: Electrophysiological properties of the canine peripheral AV conducting system. Circulation Research 26: 361 (1970).CrossRefGoogle Scholar
  58. Parmley, W.W. and Braunwald, E.: Comparative myocardial depressant and antiarrhythmic properties of d-propranolol, dl-propranolol and quinidine. Journal of Pharmacology and Experimental Therapeutics 158: 11 (1967).PubMedGoogle Scholar
  59. Paulay, K.; Weisfogel, G. and Damato, A.: Sinus node re-entry: The effect of quinidine. American Journal of Cardiology 31: 152 (1973).CrossRefGoogle Scholar
  60. Powell, C.E. and Slater, I.H.: Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. Journal of Pharmacology and Experimental Therapeutics 122: 480 (1958).PubMedGoogle Scholar
  61. Rosati, R.; Alexander, J.A.; Schaal, S.F. and Wallace, A.G.: Influence of diphenylhydantoin on electrophysiological properties of the canine heart. Circulation Research 21: 757 (1967).PubMedCrossRefGoogle Scholar
  62. Rosen, M. and Hoffman, B.: Mechanisms of action of antiarrhythmic drugs. Circulation Research 32: 1 (1973).PubMedCrossRefGoogle Scholar
  63. Shand, D.G.: Pharmacokinetic properties of the β-adrenergic receptor blocking drugs. Drugs (in press 1973).Google Scholar
  64. Singer, D.H.; Yeh, B.K.; Scherlag, B.J. and Hoffman, B.F.: Beta blockade and the specialised conduction system of the heart. Circulation 29: and 30 (Suppl. 3): 160 (1964).Google Scholar
  65. Singer, D.H. and Ten Eick, R.E.: Pharmacology of cardiac arrhythmias. Progress in Cardiovascular Disease 11: 488 (1969).CrossRefGoogle Scholar
  66. Solberg, L.E.; Singer, D.H. and Ten Eick, R.E: Electrophysiological study of myocardial infarction in dogs. Federation Proceedings 31: 387 (1972).Google Scholar
  67. Stanton, H.C.; Kirchgessner, T. and Parmenter, K.: Cardiovascular pharmacology of two new beta adrenergic receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 149: 174 (1965).PubMedGoogle Scholar
  68. Stern, S.: Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. American Heart Journal 74: 170 (1967).PubMedCrossRefGoogle Scholar
  69. Surawicz, B.: Role of electrolytes in etiology and management of cardiac arrhythmias. Progress in Cardiovascular Disease 8: 364 (1966).CrossRefGoogle Scholar
  70. Szekeres, L. and Vaughan Williams, E.M.: Antifibrillatory action. Journal of Physiology 160: 470 (1962).PubMedGoogle Scholar
  71. Taylor, J.; Kosowsky, B. and Lown, B.: Complications of procainamide in a prospective antiarrhythmic study. Circulation 44 (Suppl. 2): 43 (1971).Google Scholar
  72. Thomson, P.; Rowland, M.; Conn, K.; Steinbrunn, W. and Melmon, K.L.: Critical differences in the pharmacokinetics of lidocaine between normal and congestive heart failure patients. Clinical Research 17: 140 (1969).Google Scholar
  73. Tsolakas, T.C.; Davies, J.P.H. and Oram, S.: Propranolol in attempted maintenance of sinus rhythm after electrical defibrillation. Lancet: 1064 (1964).Google Scholar
  74. Unger, A.H. and Sklaroff, H.J.: Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias. Journal of the American Medical Association 200: 335 (1967).PubMedCrossRefGoogle Scholar
  75. Vaughan Williams, E.M. The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records. British Journal of Pharmacology 13: 276 (1958).Google Scholar
  76. Wallace, A.G.; Troyer, W.H.; Lesage, M.A. and Zotti, E.F.: Electrophysiologic effects of isoproterenol and beta-blocking agents in awake dogs. Circulation Research 18: 140 (1966).CrossRefGoogle Scholar
  77. Watanabe, Y. and Dreifus, L.S.: Interactions of lanatoside C and potassium on atrioventricular conduction in rabbits. Circulation Research 27: 931 (1970).PubMedCrossRefGoogle Scholar
  78. Weidmann, S.: The effect of the cardiac membrane potential on the rapid availability of the sodium carrier system. Journal of Physiology 127: 213 (1955).PubMedGoogle Scholar
  79. West, T.C.: Ultramicroelectrode recording from the cardiac pacemaker. Journal of Pharmacology and Experimental Therapeutics 115: 283 (1955).PubMedGoogle Scholar
  80. West, T.C. and Amory, D.W.: Single fibre recording of the effect of quinidine at atrial pacemaker sites in the isolated right atrium of the rabbit. Journal of Pharmacology and Experimental Therapeutics 130: 183 (1960).PubMedGoogle Scholar
  81. Zelis, R.; Mason, D.T.; Spann, J.F.Jr. and Braunwald, E.: Effects of ventricular stimulation and potassium administration on digitalis-induced arrhythmias. American Journal of Cardiology 25: 428 (1970).PubMedCrossRefGoogle Scholar

Copyright information

© Adis International 1973

Authors and Affiliations

  • Dean T. Mason
    • 1
  • A. N. DeMaria
    • 1
  • E. A. Amsterdam
    • 1
  • R. Zelis
    • 1
  • R. A. Massumi
    • 1
  1. 1.Section of Cardiovascular Medicine, Departments of Medicine, Physiology and PharmacologyUniversity of California, School of MedicineDavisUSA

Personalised recommendations